GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China SXT Pharmaceuticals SXTC · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.10

+9.54%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$1.1m

FY2017FY2026

Net income

−$6.2m

FY2017FY2026

Free cash flow

−$4.0m

FY2017FY2026

Shareholders' equity

$29.7m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$1.1m$1.7m$1.9m$2.0m$2.6m$4.8m$5.2m$7.0m$7.0m$4.9m
Research and development$178,765$191,393$184,194———————
Operating income−$7.1m−$2.7m−$2.6m−$5.5m−$5.4m−$2.2m−$1.3m$1.8m$1.6m$1.6m
Net income−$6.2m−$3.3m−$3.1m−$5.9m−$5.7m−$2.7m−$10.3m$1.5m$1.2m$1.2m
Diluted earnings per share-6.48-5.64-1.27-6.84-13.29-52.75-357.22114.87112.04115.06

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$34.8m$21.7m$23.1m$29.6m$33.5m$34.5m$21.7m$17.5m$7.7m$5.4m
Cash and short-term investments$28.2m$18.1m$12.1m$17.4m$15.5m$13.3m$7.3m$9.1m$560,252$65,570
Total liabilities$5.0m$6.2m$9.2m$14.9m$17.1m$18.6m$12.3m$6.4m$4.4m$3.6m
Debt$1.1m$807,200$2.4m$3.5m$2.0m$40,000$6.7m$300,000$390,000$300,000
Shareholders' equity$29.7m$15.4m$13.9m$14.7m$16.4m$16.0m$9.4m$11.1m$3.3m$1.9m
Shares outstanding1m1m2m1m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$4.0m−$2.3m−$1.9m−$80,757−$2.4m−$1.3m$934,247$239,192$1.9m$293,042
Capital spending−$4−$2,023−$7,063−$70,684−$62,490−$93,044−$406,658−$610,085−$1.1m−$186,308
Free cash flow−$4.0m−$2.3m−$1.9m−$151,441−$2.4m−$1.4m$527,589−$370,893$869,436$106,734
Dividends paid———————−$2.4m——

Latest quarters

By quarter end

Jun 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Revenue$1.2m$255,741$626,570$455,709$911,400$455,709$829,500$414,745
Operating income−$784,008−$392,004−$6.3m−$1.0m−$2.0m−$1.0m−$638,300−$319,134
Net income$163,718$81,858−$6.4m−$1.3m−$2.5m−$1.3m−$802,600−$401,284
Diluted earnings per share0.170.14-10.87-2.13-153.53-0.51-298.35-0.16
Cash from operations−$2.0m−$1.0m−$1.0m—————
Total assets$34.8m$34.8m$26.4m$21.7m$21.7m$21.7m$30.0m$31.0m
Cash and short-term investments$28.2m$28.3m$21.2m$18.1m—$18.2m—$18.5m
Debt$423,154$423,154$1.1m$772,194$96,264$772,194—$9.6m
Shareholders' equity$29.7m$29.7m$20.2m$15.4m$15.4m$15.4m$10.2m$15.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-18.4%-25.8%-11.7%
Operating income9.3%26.5%—
Net income1.5%17.7%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-347.5%-265.0%-179.9%-51.3%
Net margin-338.0%-276.2%-191.8%-79.4%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-0.5-123952.8-69493.4-100686.6-176917.3-22058.8-6594.8
Price to sales2.6——————

Share price return

Finished calendar years

2025202420232022202120202019
Return1057%-83%-86%111%-47%-58%-81%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 26 Oct 2026
  • 80-to-1 reverse split · 10 Aug 2026
  • 150-to-1 reverse split · 3 Feb 2026
  • 8-to-1 reverse split · 25 Feb 2025
  • 25-to-1 reverse split · 5 Oct 2023
  • 20-to-1 reverse split · 19 May 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.